Document:

Exhibit 10.1

 

AMENDED SEPARATION AGREEMENT

BETWEEN:

BIONIK LABORATORIES CORP.

(“Bionik”)

and

PETER BLOCH

(“Mr. Bloch”)

 

Mr. Bloch and Bionik agree on a revision
to Mr. Bloch’s terms of separation from Bionik (pursuant to that certain Agreement between Bionik and Mr. Bloch effective
as of September 1, 2017; the “Separation Agreement”) as follows:

 

		1.	Amounts payable to Mr. Bloch pursuant to section 5.4 of his July 7, 2014 employment agreement
and the corresponding section(s) of the Separation Agreement, which includes severance and all past-due bonuses, as of the date
hereof equals US$784,874.94, will be paid as follows and pursuant to the attached Excel spreadsheet:

		a.	The amount owing will be paid out over 12 months from February 2018 to January 2019.

		b.	Equal bi-monthly payments will be made from March 2018 through November 2018 of US$29,350.96 (US$58,701.92
per month) paid twice a month subject to statutory tax withholdings.

		c.	No payment will be made in December 2018, with a double payment of US$117,403.85 subject to statutory
tax withholdings being made in January 2019, in 2 equal installments.

		d.	The payment of US$117,403.85 (US$58,701.92 for each of January and February 2018) payable subject
to statutory tax withholdings will paid on signing of this agreement.

		2.	Mr. Bloch’s consulting fee of US$15,000 plus refundable HST for the period of November 16
to November 30, 2017, is payable on signing of this contract.

		3.	Bionik Group benefit plan (provided through GWL), will continue on a monthly basis for 18 months
from January 2018 through to June 2019. Health Spending Account (HSA) will continue to the end of 2018 in full at $750 and payable
in December 2018, and prorated to $375 in 2019 and payable in June 2019. Receipts for HSA continue to be required.

		4.	RRSP matching program. Both Mr. Bloch and Bionik will contribute 5% in to the RRSP matching program,
the following will apply:

i.       Amounts
will be withheld in accordance with then-current payroll practices and, along with Bionik matching amounts, will be directed to
existing RRSP account.

ii.      If
and when the maximum RRSP contribution for 2018 and 2019 have been made (from a combination of Mr. Bloch’s up to 5% contribution
and Bionik’s matching contribution), the remaining amount of the Company’s match, if any, will be paid out on a monthly
basis to the existing investment account

 

		5.	The permissible terms for the exercise of all Mr. Bloch’s stock options shall be 2 years
from the date that he leaves Bionik as a consultant, as stated in the Separation Agreement dated August 9, 2017.

 

     

     

    

 

The parties acknowledge and agree that
the amounts described above are the only amounts due and owing to Mr. Bloch by Bionik, and no other amounts are due or owing to
Mr. Bloch from Bionik pursuant to the terms of his employment agreement, the Separation Agreement or otherwise.

 

The terms of the above revised agreement
are only effective if this agreement is signed and executed by all parties by March 15, 2018.

 

In the event that Bionik breaches any of
the payment terms set forth herein and in the attached spreadsheet (subject to a 10 day period to cure any such breach after notice
by Mr. Bloch), all monies shall become immediately due and owing, which Bionik shall pay to Mr. Bloch by certified cheque within
5 business days.

 

	March 10, 2018	 	March 13, 2018	 
	Date	 	Date	 
	 	 	 	 
	/s/ Peter Bloch	 	/s/ Eric Dusseux	 
	Peter Bloch	 	Eric Dusseux, CEO	 
	 	 	Bionik Laboratories Corp.Exhibit 10.2

 

EXCHANGE AGREEMENT

 

THIS EXCHANGE AGREEMENT
(this “Agreement”) is dated as of the 12th day of March, 2018 (the “Effective Date”),
by and between Bionik Laboratories Corp., a Delaware corporation (the “Company”), and RGD Investissements S.A.S
(the “Holder”).

 

WHEREAS, the Holder
beneficially owns and holds that certain Promissory Note, dated as of February 2, 2018, issued by the Company, in the principal
amount of $500,000 (the “$500K Note”); and

 

WHEREAS, the Holder
desires to exchange the $500K Note for one of the Company’s Convertible Promissory Notes (the “Exchange Security”)
pursuant to the Company’s convertible note offering of up to $14,000,000 (the “Offering”), and the Company
desires to issue the Exchange Security in exchange for the $500K Note, all on the terms and conditions set forth in this Agreement.

 

NOW, THEREFORE, in
consideration of the terms and conditions contained herein, and other good and valuable consideration, the receipt and sufficiency
of which is hereby acknowledged, the Company and the Holders hereby agree as follows:

 

Section 1. Exchange.
On the Effective Date, subject to and upon the terms and conditions set forth in this Agreement, the Holder shall surrender to
the Company the $500K Note and all of the rights, covenants, agreements and obligations set forth therein or contemplated thereby,
including but not limited to any interest accrued and unpaid on the principal amount of the $500K Note (“Collectively, the
“Rights”), and, in exchange therefore, the Company shall issue to the Holder the Exchange Security, with an
issue date as of February 2, 2018. The Exchange Security shall be substantially the same as the convertible promissory notes issued
by the Company pursuant to the Offering. Upon the Effective Date, the Holder will not have any interest or title in or to the $500K
Note or the Rights.

 

Section 2. Ownership
and Interest. The Holder is the record and beneficial owner of the $500K Note and the Rights, free and clear of all liens,
charges, pledges, security interests, claims, mortgages, options, encumbrances, rights of first refusal, conditions, covenants,
and other restrictions (other than any restrictions under the Securities Act of 1933, as amended, or state securities laws).

 

Section 3. Applicable
Law. This Agreement shall be construed in accordance with and governed by the laws of the State of Delaware without regard
to its conflict of law rules.

 

Section 4. Counterparts.
This Agreement may be executed in two or more identical counterparts, all of which shall be considered one and the same agreement
and shall become effective when counterparts have been signed by each party and delivered to the other party; provided that a facsimile
signature shall be considered due execution and shall be binding upon the signatory thereto with the same force and effect as if
the signature were an original, not a facsimile signature.

 

Section 5. Headings.
The headings of this Agreement are for convenience of reference and shall not form part of, or affect the interpretation of, this
Agreement.

 

     

     

    

 

Section 6. Severability.
If any provision of this Agreement shall be invalid or unenforceable in any jurisdiction, such invalidity or unenforceability shall
not affect the validity or enforceability of the remainder of this Agreement in that jurisdiction or the validity or enforceability
of any provision of this Agreement in any other jurisdiction.

 

Section 7. Entire
Agreement; Amendments. This Agreement and the Exchange Security supersede all other prior oral or written agreements between
the Holder, the Company, their affiliates and persons acting on their behalf with respect to the matters discussed herein, and
this Agreement and the instruments referenced herein contain the entire understanding of the parties with respect to the matters
covered herein and therein and, except as specifically set forth herein or therein, neither the Company nor the Holder makes any
representation, warranty, covenant or undertaking with respect to such matters; provided, however, that all representations and
warranties contained in that certain Subscription Agreement, dated as of March 8, 2018, shall be incorporated herein. No provision
of this Agreement may be amended other than by an instrument in writing signed by the Company and the Holder. No provision hereof
may be waived other than by an instrument in writing signed by the party against whom enforcement is sought.

 

Section 8. Successors
and Assigns. This Agreement shall be binding upon and inure to the benefit of the parties and their respective successors and
assigns. The Holder may not assign any of its rights hereunder without the prior written consent of the Company.

 

Section 9. No Third
Party Beneficiaries. This Agreement is intended for the benefit of the parties hereto and their respective permitted successors
and assigns, and is not for the benefit of, nor may any provision hereof be enforced by, any other person.

 

Section 10. Further
Assurances. Each party shall do and perform, or cause to be done and performed, all such further acts and things, and shall
execute and deliver all such other agreements, certificates, instruments and documents, as any other party may reasonably request
in order to carry out the intent and accomplish the purposes of this Agreement and the consummation of the transactions contemplated
hereby.

 

[Signature Pages
Follow]

 

    	 	2	 

     

    

 

IN WITNESS WHEREOF,
the parties have executed this Exchange Agreement as of the date first written above.

 

	 	BIONIK LABORATORIES CORP.	 
	 	 	 	 
	 	By:	/s/ Eric Dusseux	 
	 	Name:	Eric Dusseux	 
	 	Title:	CEO	 
	 	 	 	 
	 	RGD INVESTISSEMENTS S.A.S	 
	 	 	 	 
	 	By:	/s/ Remi Gaston-Dreyfus	 
	 	Name:	Remi Gaston-Dreyfus	 
	 	Title:	CEO	 

 

    	 	3Exhibit 10.3

 

BIONIK LABORATORIES CORP.

 

PROMISSORY NOTE

 

	Principal Amount: US$400,000.00	Issue Date: March 14, 2018

 

Bionik
Laboratories Corp., a Delaware corporation (the “Company”), for value received, hereby promises
to pay to RGD Investissements S.A.S. or its permitted assigns or successors (the “Holder”), the principal
amount of Four Hundred Thousand Dollars (US$400,000.00) (the “Principal Amount”), without demand, on
the Maturity Date (as hereinafter defined), together with any accrued and unpaid interest due thereon. This Note shall bear interest
at a fixed rate of 3% per month, beginning on the Issue Date. Interest shall be computed based on a 360-day year of twelve 30-day
months and shall be payable, along with the Principal Amount, on the Maturity Date. Payment of all principal and interest due shall
be in such coin or currency of the United States of America as shall be legal tender for the payment of public and private debts
at the time of payment.

 

1.           Definitions.

 

1.1           Definitions.
The terms defined in this Section 1 whenever used in this Note shall have the respective meanings hereinafter specified.

 

“Event
of Default” shall have the meaning set forth in Section 4.1.

 

“Holder”
or “Holders” means the Person named above or any Person who shall thereafter become a recordholder of
this Note in accordance with the terms hereof.

 

“Issue
Date” means the issue date stated above.

 

“Maturity
Date” shall mean the earlier of (i) March 31, 2018 and (ii) the date of receipt of an aggregate of $7,000,000 in
loan proceeds to the Company from the sale of a convertible promissory note to a new investor to be agreed to by the Company and
the Holder.

 

“Note”
means this Note, as amended, modified or restated.

 

“Person”
means an individual, corporation, partnership, limited liability company, association, trust, joint venture, unincorporated organization
or any government, governmental department or agency or political subdivision thereof.

 

2.           GENERAL
PROVISIONS.

 

2.1           Loss,
Theft, Destruction of Note. Upon receipt of evidence satisfactory to the Company of the loss, theft, destruction or
mutilation of this Note and, in the case of any such loss, theft or destruction, upon receipt of indemnity or security reasonably
satisfactory to the Company, or, in the case of any such mutilation, upon surrender and cancellation of this Note, the Company
will make and deliver, in lieu of such lost, stolen, destroyed or mutilated Note, a new Note of like tenor and unpaid principal
amount dated as of the date hereof. This Note shall be held and owned upon the express condition that the provisions of this Section
2.1 are exclusive with respect to the replacement of a mutilated, destroyed, lost or stolen Note and shall preclude any and
all other rights and remedies notwithstanding any law or statute existing or hereafter enacted to the contrary with respect to
the replacement of negotiable instruments or other securities without their surrender.

 

    	 	1	 

     

    

 

2.2          Prepayment.
This Note may be prepaid by the Company in whole or in part.

 

3.           STATUS;
RESTRICTIONS ON TRANSFER.

 

3.1          Status
of Note. This Note is a direct, general and unconditional obligation of the Company, and constitutes a valid and legally
binding obligation of the Company, enforceable in accordance with its terms subject, as to enforcement, to bankruptcy, insolvency,
reorganization and other similar laws of general applicability relating to or affecting creditors’ rights and to general
principles of equity. This Note does not confer upon the Holder any right to vote or to consent or to receive notice as a stockholder
of the Company, as such, in respect of any matters whatsoever, or any other rights or liabilities as a stockholder.

 

3.2          COVENANTS.
In addition to the other covenants and agreements of the Company set forth in this Note, the Company covenants and agrees that
so long as this Note shall be outstanding, if any one or more events occur which constitute or which, with the giving of notice
or the lapse of time or both, would constitute an Event of Default or if the Holder shall demand payment or take any other action
permitted upon the occurrence of any such Event of Default, the Company will forthwith give notice to the Holder, specifying the
nature and status of the Event of Default or other event or of such demand or action, as the case may be.

 

4.           REMEDIES.

 

4.1          Events
of Default. “Event of Default” wherever used herein means any one of the following events:

 

(a)          Default
in the due and punctual payment of the principal of, or any other amount owing in respect of (including interest), this Note when
and as the same shall become due and payable;

 

(b)          Default
in the performance or observance of any covenant or agreement of the Company in this Note (other than a covenant or agreement a
default in the performance of which is specifically provided for elsewhere in this Section 4.1), and the continuance of
such default for a period of 10 days after there has been given to the Company by the Holder a written notice specifying such default
and requiring it to be remedied;

 

(c)          The
entry of a decree or order by a court having jurisdiction adjudging the Company as bankrupt or insolvent; or approving as properly
filed a petition seeking reorganization, arrangement, adjustment or composition of or in respect of the Company under the Federal
Bankruptcy Code or any other applicable federal or state law, or appointing a receiver, liquidator, assignee, trustee or sequestrator
(or other similar official) of the Company or of any substantial part of its property, or ordering the winding-up or liquidation
of its affairs, and the continuance of any such decree or order unstayed and in effect for a period of 60 calendar days;

 

    	 	2	 

     

    

 

(d)          The
institution by the Company of proceedings to be adjudicated as bankrupt or insolvent, or the consent by it to the institution of
bankruptcy or insolvency proceedings against it, or the filing by it of a petition or answer or consent seeking reorganization
or relief under the Federal Bankruptcy Code or any other applicable federal or state law, or the consent by it to the filing of
any such petition or to the appointment of a receiver, liquidator, assignee, trustee or sequestrator (or other similar official)
of the Company or of any substantial part of its property, or the making by it of an assignment for the benefit of creditors;

 

(e)          The
Company seeks the appointment of a statutory manager or proposes in writing or makes a general assignment or an arrangement or
composition with or for the benefit of its creditors or any group or class thereof or files a petition for suspension of payments
or other relief of debtors or a moratorium or statutory management is agreed or declared in respect of or affecting all or any
material part of the indebtedness of the Company; or

 

(f)          It
becomes unlawful for the Company to perform or comply with its obligations under this Note.

 

4.2          Effects
of Default. If an Event of Default occurs and is continuing, then and in every such case the Holder may declare this
Note to be due and payable immediately, by a notice in writing to the Company, and upon any such declaration, the Company shall
pay to the Holder the outstanding principal amount of this Note plus all accrued and unpaid interest through the date the Note
is paid in full.

 

4.3          Remedies
Not Waived; Exercise of Remedies. No course of dealing between the Company and the Holder or any delay in exercising
any rights hereunder shall operate as a waiver by the Holder. No failure or delay by the Holder in exercising any right, power
or privilege under this Note shall operate as a waiver thereof nor shall any single or partial exercise thereof preclude any other
or further exercise thereof or the exercise of any other right, power or privilege.

 

5.           MISCELLANEOUS.

 

5.1          Severability.
If any provision of this Note shall be held to be invalid or unenforceable, in whole or in part, neither the validity nor the enforceability
of the remainder hereof shall in any way be affected.

 

5.2          Notice.
Where this Note provides for notice of any event, such notice shall be given (unless otherwise herein expressly provided) in writing
and either (a) delivered personally, (b) sent by certified, registered or express mail, postage prepaid or (c) sent by facsimile
or other electronic transmission, and shall be deemed given when so delivered personally, sent by facsimile or other electronic
transmission (confirmed in writing) or mailed. Notices shall be addressed, if to Holder, to its address as provided in the books
and records of the Company or, if to the Company, to its principal office.

 

    	 	3	 

     

    

 

5.3           Governing
Law. This Note shall be governed by, and construed in accordance with, the laws of the State of Delaware (without giving
effect to any conflicts or choice of law provisions that would cause the application of the domestic substantive laws of any other
jurisdiction).

 

5.4           Forum.
The Holder and the Company hereby agree that any dispute which may arise out of or in connection with this Note shall be adjudicated
before a court of competent jurisdiction in the State of Delaware and they hereby submit to the exclusive jurisdiction of the courts
of the State of Delaware, as well as to the jurisdiction of all courts to which an appeal may be taken from such courts, with respect
to any action or legal proceeding commenced by either of them and hereby irrevocably waive any objection they now or hereafter
may have respecting the venue of any such action or proceeding brought in such a court or respecting the fact that such court is
an inconvenient forum.

 

5.5           Headings.
The headings of the Articles and Sections of this Note are inserted for convenience only and do not constitute a part of this Note.

 

5.6           Amendments.
This Note may be amended or waived only with the written consent of the Company and the Holder.

 

5.7           No
Recourse Against Others. The obligations of the Company under this Note are solely obligations of the Company and no
officer, employee or stockholder shall be liable for any failure by the Company to pay amounts on this Note when due or perform
any other obligation.

 

5.8           Assignment;
Binding Effect. This Note may be assigned by the Company without the prior written consent of the Holder. This Note
shall be binding upon and inure to the benefit of both parties hereto and their respective permitted successors and assigns.

 

Signature
on the Following Page

 

    	 	4	 

     

    

 

In
Witness Whereof, the Company has caused this Note to be signed by its duly authorized officer on the date hereinabove
written.

 

	 	Bionik Laboratories Corp.
	 	 	 
	 	By:	/s/ Eric Dusseux
	 	Name:	Eric Dusseux
	 	Title:	CEO

 

Signature
Page to Promissory Note

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00280-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00280-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00280-of-00352.parquet"}]]